NR4A1 and breast carcinoma: There was insufficient evidence to support other characteristics, including race, age, PD-L1 expression, clinical stage, hormone receptor (HR) status, menopausal status, Eastern Cooperative Oncology Group (ECOG) performance status, and T stage, as predictive biomarkers to guide patient selection for neoadjuvant immunotherapy in breast cancer.<h4>Conclusion</h4>Neoadjuvant immunotherapy was associated with favorable outcomes in breast cancer.